We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Tenax Therapeutics Inc | NASDAQ:TENX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.24 | -3.70% | 6.24 | 6.12 | 6.50 | 6.53 | 6.1642 | 6.53 | 19,004 | 21:14:32 |
From Oct 2024 to Jan 2025
Format: Fireside Chat Presenter: Chris Giordano, President & Chief Executive OfficerDate and time: November 13, 2024 at 1:00 PM EST Webcast: https://wsw.com/webcast/guggen/tenx/1967811
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize I.V., subcutaneous, and oral formulations of levosimendan. Tenax also is developing a unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax’s common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contacts
Investor Contact:John FrauncesManaging DirectorLifeSci Advisors, LLCC: 917-355-2395, or
Brian MullenLifeSci Advisors, LLCC: 203-461-1175
1 Year Tenax Therapeutics Chart |
1 Month Tenax Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
